Summary
Eli Lilly and Company (LLY) announced a change to its Board of Directors with the election of Gabrielle Sulzberger, effective January 25, 2021. This appointment increases the size of the Board to fourteen members. Ms. Sulzberger brings extensive financial and strategic expertise, with a background in private equity, including a focus on socially responsible investing, and prior executive experience as a chief financial officer. Her qualifications include service on numerous public company boards, and she holds advanced degrees from Princeton, Harvard Business School, and Harvard Law School. Ms. Sulzberger's appointment is significant as she will serve on the Audit Committee and the Ethics and Compliance Committee, underscoring her role in key governance functions. The Board has affirmed her independence according to NYSE, SEC, and company guidelines. Investors should note that Ms. Sulzberger will be subject to the company's standard director compensation program and will stand for election at the upcoming annual shareholder meeting.
Key Highlights
- 1Gabrielle Sulzberger elected to the Board of Directors, effective January 25, 2021.
- 2Board size increased to fourteen members.
- 3Ms. Sulzberger possesses significant financial and strategic advisory experience, with a background in private equity.
- 4She has prior experience as CFO of public and private companies.
- 5Ms. Sulzberger brings extensive board experience, including current roles with MasterCard, Brixmor Property Group, and Cerevel Therapeutics.
- 6She will serve on the Audit Committee and the Ethics and Compliance Committee, indicating a focus on governance.
- 7The company confirmed Ms. Sulzberger meets independence standards for the NYSE, SEC, and company guidelines.